Veterinary Sciences Centre, University College Dublin, Belfield, Dublin, Ireland.
Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Belfield, Dublin, Ireland.
J Gen Virol. 2023 Feb;104(2). doi: 10.1099/jgv.0.001821.
A novel proprietary formulation, ViruSAL, has previously been demonstrated to inhibit diverse enveloped viral infections and . We evaluated the ability of ViruSAL to inhibit SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) infectivity using physiologically relevant models of the human bronchial epithelium, to model early infection of the upper respiratory tract. ViruSAL potently inhibited SARS-CoV-2 infection of human bronchial epithelial cells cultured as an air-liquid interface (ALI) model, in a concentration- and time-dependent manner. Viral infection was completely inhibited when ViruSAL was added to bronchial airway models prior to infection. Importantly, ViruSAL also inhibited viral infection when added to ALI models post-infection. No evidence of cellular toxicity was detected in ViruSAL-treated cells at concentrations that completely abrogated viral infectivity. Moreover, intranasal instillation of ViruSAL to a rat model did not result in any toxicity or pathological changes. Together these findings highlight the potential for ViruSAL as a novel and potent antiviral for use within clinical and prophylactic settings.
一种新型专利配方 ViruSAL 此前已被证明能够抑制多种包膜病毒感染。我们评估了 ViruSAL 抑制 SARS-CoV-2（严重急性呼吸综合征冠状病毒-2）感染的能力，使用人类支气管上皮细胞的生理相关模型，模拟上呼吸道的早期感染。ViruSAL 以浓度和时间依赖的方式强烈抑制培养的作为气液界面 (ALI) 模型的人支气管上皮细胞中的 SARS-CoV-2 感染。在感染前将 ViruSAL 添加到支气管气道模型中时，病毒感染完全被抑制。重要的是，当将 ViruSAL 添加到感染后的 ALI 模型中时，也抑制了病毒感染。在完全消除病毒感染性的浓度下，ViruSAL 处理的细胞中未检测到细胞毒性的证据。此外，鼻内滴注 ViruSAL 到大鼠模型中不会导致任何毒性或病理变化。这些发现共同强调了 ViruSAL 作为一种新型强效抗病毒药物在临床和预防环境中的应用潜力。
